Trip Database Blog

It doesn’t have to be Spanish, it could be French, German, Italian etc

In our embrace of LLMs I was wondering about their use in translation. We did this translation:

Spanish original: Tengo osteoporosis. Columna lumbar T-score -3.3. Cadera izda T-score -1.0. Se me ha producido fractura con aplastamiento y edema D11. La reumatóloga me ha mandado Denosumab. He leído efectos secundarios y no se qué hacer. Gracias

English translation: I have osteoporosis. Lumbar spine T-score -3.3. Left hip T-score -1.0. I have experienced a compression fracture with edema at T11. My rheumatologist prescribed Denosumab. I have read about the side effects and I don’t know what to do. Thank you.

Apparently this is very accurate. Could we harness this power into Trip? Allowing such roles as:

• Translate Spanish/German/Italian etc terms into their English equivalent to use within Trip
• Non-native English users being able to check their translated (English) terms
• Allowing free-text questions, in non-English, and searching Trip and getting the results page translated into Spanish etc
• Use any Q&A system we release to allow questions in Spanish/German/French etc and give the reply in the language of choice

In our recent work on automated Q&A we posted an answer to the question What is the Role of H. pylori Eradication in Asymptomatic Individuals? The final recommendation was:

“For asymptomatic individuals, H. pylori eradication should be considered on a case-by-case basis, prioritizing those with gastric cancer risk factors (e.g., family history, high-prevalence areas). Universal eradication is not supported by current guidelines in low-risk populations.“

Spanish translation: Para individuos asintomáticos, se debe considerar la erradicación de H. pylori de forma individualizada, priorizando a aquellos con factores de riesgo de cáncer gástrico (por ejemplo, antecedentes familiares, áreas de alta prevalencia). La erradicación universal no cuenta con el respaldo de las guías actuales en poblaciones de bajo riesgo.

German translation: Für asymptomatische Personen sollte die H. pylori-Eradikation fallweise in Betracht gezogen werden, wobei Personen mit Risikofaktoren für Magenkrebs (z. B. familiäre Vorbelastung, Gebiete mit hoher Prävalenz) priorisiert werden sollten. Eine universelle Eradikation wird von den aktuellen Leitlinien in Bevölkerungsgruppen mit geringem Risiko nicht unterstützt.

Japanese translation: 無症状の個人に対しては、H. pylori の除菌を症例ごとに検討し、胃がんのリスク因子（例：家族歴、高い有病率の地域）を持つ人を優先するべきです。低リスク集団においては、現在のガイドラインでは普遍的な除菌は推奨されていません。

I expect these are all good translations!

Resource is a potential issue, these translations are not free and if it proves popular it might be too heavy a burden (anyone know of any funding opportunities?). However, the benefits are huge. It would immediately open up the English-language evidence-base to people who can’t speak English. In addition it could support non-native English speakers to get the most out of Trip.

Déjame saber qué piensas. (Spanish)
Fais-moi savoir ce que tu penses. (French)
Lass mich wissen, was du denkst. (German)
Fammi sapere cosa ne pensi. (Italian)
Me diz o que você acha. (Portuguese)
Дай мне знать, что ты думаешь. (Russian)
让我知道你的想法。 (Chinese – Simplified)
讓我知道你的想法。 (Chinese – Traditional)
あなたの考えを教えてください。 (Japanese)
네 생각을 알려줘. (Korean)
دعني أعرف ما هو رأيك. (Arabic)
Laat me weten wat je denkt. (Dutch)
मुझे बताएं कि आप क्या सोचते हैं। (Hindi)
Ne düşündüğünü bana söyle. (Turkish)
Låt mig veta vad du tycker. (Swedish)
Daj mi znać, co myślisz. (Polish)
Cho tôi biết bạn nghĩ gì. (Vietnamese)
บอกให้ฉันรู้ว่าคุณคิดอย่างไร (Thai)
Πες μου τη γνώμη σου. (Greek)

We continue our work exploring LLMs and we’ve done more work based on last week’s question What is the Role of H. pylori Eradication in Asymptomatic Individuals?. We have asked the LLM to identify, from the question and answer, any research gaps. The response is below. It looks comprehensive, but is it any good?

---

1. Data on Low-Risk Populations

• Gap: Limited evidence on the role of H. pylori eradication in asymptomatic individuals from low-risk populations (e.g., North America, Western Europe), where gastric cancer incidence is lower.
• Rationale: Most studies focus on high-risk regions, leaving uncertainty about the cost-effectiveness and clinical impact of eradication in low-risk settings.

---

2. Adverse Effects and Risks of Eradication Therapy

• Gap: Insufficient discussion of the adverse effects and risks associated with eradication therapy, including:
  • Antibiotic resistance and its impact on treatment efficacy.
  • Side effects of eradication regimens (e.g., gastrointestinal discomfort, allergic reactions).
  • Potential disruption of the gut microbiome and long-term consequences.
• Rationale: A balanced assessment of risks versus benefits is crucial, especially for asymptomatic individuals who may not immediately benefit from treatment.

---

3. Impact on Non-Gastric Conditions

• Gap: Limited exploration of the systemic effects of H. pylori eradication on non-gastric conditions, such as:
  • Potential protective effects against asthma, inflammatory bowel disease, or other immune-modulated conditions.
  • Potential risks, such as increased incidence of GERD or esophageal adenocarcinoma.
• Rationale: Understanding the broader health implications of eradication is essential for informed decision-making.

---

4. Cost-Effectiveness in Diverse Healthcare Systems

• Gap: Lack of detailed cost-effectiveness analyses across different healthcare systems and economic settings, including:
  • Comparison of eradication programs with other preventive strategies (e.g., endoscopic screening).
  • Economic barriers to implementation in low- and middle-income countries.
• Rationale: Cost-effectiveness is critical for policy-making and resource allocation, especially in diverse global contexts.

---

5. Long-Term Follow-Up Data

• Gap: Insufficient long-term data on the durability of benefits and potential late adverse effects of eradication, particularly in:
  • Low-risk populations.
  • Subgroups with specific genetic or comorbid conditions.
• Rationale: Long-term studies are needed to assess the sustainability of eradication benefits and identify any delayed risks.

---

6. Optimal Screening Strategies

• Gap: Limited evidence on the most effective and cost-efficient screening protocols for asymptomatic individuals, including:
  • Tailored strategies for different demographic groups (e.g., age, genetic risk factors).
  • Integration of screening with other preventive health measures.
• Rationale: Effective screening strategies are essential for identifying individuals who would benefit most from eradication.

---

7. Role of Probiotics and Adjunct Therapies

• Gap: Lack of detailed discussion on the role of probiotics and adjunct therapies in improving eradication outcomes, including:
  • Effectiveness of specific probiotic strains or formulations.
  • Potential for adjunct therapies to reduce side effects or enhance eradication rates.
• Rationale: Adjunct therapies could optimise eradication protocols, but more evidence is needed to guide their use.

---

8. Ethical Considerations

• Gap: Absence of discussion on ethical considerations related to treating asymptomatic individuals, such as:
  • Balancing the benefits of prevention against the risks of unnecessary treatment.
  • Ensuring informed consent in population-based eradication programs.
• Rationale: Ethical considerations are critical for public health interventions, particularly when treating individuals who may never develop complications.

---

9. Impact of Vaccination (Future Directions)

• Gap: Limited exploration of vaccination as an alternative or complementary strategy to eradication therapy, including:
  • Current progress in H. pylori vaccine development.
  • Potential impact of vaccination on the need for eradication in asymptomatic individuals.
• Rationale: Vaccination could revolutionise H. pylori management, but its role remains underexplored.

---

10. Subgroup and Population-Specific Data

• Gap: Insufficient data on how subpopulations (e.g., by age, genetic factors, or comorbid conditions) respond to eradication therapy.
• Rationale: Tailored interventions based on subgroup-specific data could improve the efficacy and safety of eradication programs.

---

11. Long-Term Impact Beyond Cancer Prevention

• Gap: Limited understanding of the long-term impact of eradication on gastric physiology and overall health, including:
  • Potential benefits (e.g., reduced inflammation, improved nutrient absorption).
  • Unintended consequences (e.g., changes in gastric acid secretion, microbiome alterations).
• Rationale: A comprehensive understanding of long-term effects is necessary to weigh the risks and benefits of eradication.

---

Summary of Rationalised Knowledge Gaps

Gap	Details
Low-risk populations	Limited data on benefits in regions with low gastric cancer incidence.
Adverse effects of eradication	Risks and side effects of eradication therapy in asymptomatic individuals.
Non-gastric conditions	Impact of eradication on immune modulation and other diseases.
Cost-effectiveness	Economic analyses in diverse healthcare systems.
Long-term follow-up data	Durability of benefits and late adverse effects.
Optimal screening strategies	Effective and cost-efficient screening protocols for diverse populations.
Role of probiotics and adjuncts	Effectiveness of probiotics and adjunct therapies in eradication regimens.
Ethical considerations	Ethical implications of treating asymptomatic individuals.
Vaccination	Potential role of vaccination as an alternative strategy.
Subgroup-specific data	Response to eradication in subpopulations (e.g., age, genetics, comorbidities).
Long-term impact beyond cancer	Broader effects of eradication on gastric physiology and overall health.

---

Addressing the Gaps

To address these gaps, future research and reviews should:

1. Include studies from low-risk populations to assess the universal applicability of eradication programs.
2. Evaluate the risks and side effects of eradication therapy in asymptomatic individuals.
3. Investigate the systemic effects of H. pylori eradication on non-gastric conditions.
4. Conduct cost-effectiveness analyses in diverse economic settings.
5. Extend long-term follow-up studies to assess the durability of benefits and late adverse effects.
6. Develop and evaluate optimal screening strategies for diverse populations.
7. Explore the role of probiotics and adjunct therapies in improving eradication outcomes.
8. Discuss ethical considerations in population-based eradication programs.
9. Investigate the potential of vaccination as a preventive strategy.
10. Generate subgroup-specific data to tailor eradication interventions.
11. Study the long-term impact of eradication on gastric physiology and overall health.

By addressing these gaps, the evidence base can be strengthened, leading to more informed and balanced recommendations for H. pylori eradication in asymptomatic individuals.

We’ve been really busy of late! The Mind Maps have just been released, the systematic review scoring system is nearly finished and we’ve been having lots of fun with automated clinical question answering. Next up, we’re tackling mobile optimisation, as we know the current experience isn’t where it should be.

Now, we’re planning the next round of improvements – and we need your input. Over the past 25 years, Trip has grown by listening to our users, and we’re continuing that tradition. Your feedback has shaped Trip, and now it’s time for more of it.

We’ve put together a short survey to explore different aspects of your search experience. It covers six key themes, with just a few questions in each, taking no more than 15 minutes to complete. Your insights will directly help us make Trip better for you and for other users.

We’d love for you to take part every response counts!

Click here to take part in the survey 🙂

We host one of the largest dedicated collections of systematic reviews on the web, with over 550,000 reviews available. With this vast resource comes a responsibility: ensuring that users critically assess the validity of the systematic reviews they access.

Systematic reviews sit at the top of the evidence pyramid/hierarchy, but their inclusion in this category does not automatically guarantee high-quality evidence. While well-conducted systematic reviews deserve their status, many are poorly executed and risk misleading users.

To address this, we are developing a scoring system designed to help users gauge the reliability of systematic reviews. By identifying markers of both rigorous methodology and potential weaknesses, this system will generate a score displayed alongside each review, providing a quick and informed assessment of its credibility. Below is a mock-up of how each score will look:

There are 4 graphics of which 3 are actual, meaningful, scores:

• Appears promising
• Potential concerns
• Bad

We’re working through a few issues but everything is looking promising for a release in the near future (famous last words).

We’ve been having a lot of fun working hard on an automated Q&A system – we’ve been working on and off for over 12 months. Recently we’ve made some big strides and below is an example Q&A. It’s impressive (although I could easily be accused of being biased)!

What is the Role of H. pylori Eradication in Asymptomatic Individuals?

Helicobacter pylori (H. pylori) is a bacterium that infects the stomach lining and is a leading cause of peptic ulcer disease, gastritis, and gastric cancer. While many infected individuals remain asymptomatic, H. pylori is classified as a Group 1 carcinogen by the World Health Organization (WHO) due to its association with gastric cancer. The question of whether to treat asymptomatic individuals is debated, with considerations including the potential to reduce gastric cancer risk and the risks of antibiotic resistance and microbiome disruption.

---

1. Does Eradication of H. pylori Reduce Gastric Cancer Risk?

Evidence from Meta-Analyses and Clinical Trials:

• A meta-analysis of randomized controlled trials found that H. pylori eradication reduced the incidence of gastric cancer by approximately 34% (Ford et al., 2014).
• Another systematic review and meta-analysis concluded that individuals who received eradication therapy had a 38% reduction in gastric cancer incidence (Lee et al., 2016).
• A cost-effectiveness study using a Markov model showed that a screen-and-treat approach was both effective in preventing gastric cancer and cost-saving in the long term, particularly in high-risk populations (Areia et al., 2013).

Applicability to Western Populations:

• Most studies demonstrating the benefits of eradication are from Asian populations, where the background incidence of gastric cancer is high. The applicability to Western populations, where gastric cancer incidence is lower, remains uncertain (Sugano et al., 2015).

---

2. Are There Official Guidelines Supporting Eradication in Asymptomatic Individuals?

Evidence from Guidelines:

• 2022 Chinese National Clinical Guideline: Recommends screening and treatment for H. pylori in high-risk populations but does not advocate for universal eradication in asymptomatic individuals (Liu et al., 2022).
• Saudi H. pylori Working Group: Provides management recommendations but does not support mass eradication in asymptomatic individuals (Alrashed et al., 2021).
• ESPGHAN/NASPGHAN Guidelines: Focus on treatment for children and adolescents with symptoms rather than asymptomatic individuals (Jones et al., 2017).

Targeted “Screen-and-Treat” Strategy:

• A study in the U.S. population found that targeted eradication for individuals with a family history of gastric cancer was beneficial (Choi et al., 2018).

---

3. Are There Risks Associated with Eradication?

Evidence-Based Risks:

• Antibiotic Resistance: Rising resistance rates to common H. pylori treatments (e.g., clarithromycin, metronidazole) are a significant concern, particularly in regions with high antibiotic use (Savoldi et al., 2018).
• Gastrointestinal Microbiome Disruption: Eradication therapy can alter the gut microbiome, potentially leading to dysbiosis and other gut-related symptoms (Ianiro et al., 2016).

Theoretical Risks:

• In low-risk individuals, the benefits of treatment may not outweigh the risks, particularly given the potential for antibiotic resistance and microbiome disruption.

---

4. Summary and Recommendations

Evidence-Based Recommendations:

• H. pylori eradication reduces gastric cancer risk, particularly in high-risk groups (e.g., those with a family history of gastric cancer or living in high-prevalence regions) (Ford et al., 2014).
• Screen-and-treat strategies are cost-effective in high-risk populations (Areia et al., 2013).

Guideline Recommendations:

• Current guidelines recommend a selective approach rather than mass eradication, particularly in low-risk Western populations (Sugano et al., 2015).

Risks to Consider:

• The risks of antibiotic resistance and microbiome disruption must be weighed against the potential benefits of eradication (Savoldi et al., 2018).

---

Final Recommendation

For asymptomatic individuals, H. pylori eradication should be considered on a case-by-case basis, prioritizing those with gastric cancer risk factors (e.g., family history, high-prevalence areas). Universal eradication is not supported by current guidelines in low-risk populations.

---

Key References:

1. Ford et al., 2014
2. Lee et al., 2016
3. Areia et al., 2013
4. Sugano et al., 2015
5. Savoldi et al., 2018

I just had an interesting discussion with a group of NHS librarians from NHS Wales about Trip and the use of LLMs. Most of the features I highlighted were geared towards health professionals, which made me feel a bit guilty about not focusing more on their needs.

So, at the end of the discussion, I suggested an idea that could benefit a wider audience: using LLMs to analyse past user searches on a given topic and generate related search terms (often a problem for information specialists – identifying additional terms to use in a search). I’ve often thought this could be valuable – essentially harnessing the collective wisdom of our users to improve search experiences.

To test this concept, I took a large list of searches related to urinary tract infections (UTIs) and asked ChatGPT to analyze them. The result? A structured mind map that categorizes searches into key themes, making it easier to explore related topics more effectively:

It looks nice, but is it useful?

To accommodate the wonderful Mind Maps feature we’ve had to redesign the navigation bar at the top of the results page, which now looks like this:

Clicking on the ‘Display options’ reveals the features that were previously in view:

Hopefully nothing too controversial there…

We’re really excited to announce the launch of our mind map feature, our second AI product (after ‘Latest evidence’)!

A mind map is – according to ChatGPT: A mind map is a visual tool used to organize information, ideas, or concepts in a structured, non-linear way. It starts with a central idea or topic, from which related ideas branch out in a radial fashion. Each branch can have sub-branches, creating a network of connected thoughts. Mind maps help with brainstorming, problem-solving, studying, and planning by making complex information easier to understand and remember. They typically use keywords, colors, and images to enhance creativity and recall.

Seeing an image will better help understand the concept, but to start you need to understand how to create one! Firstly, do a search and at the top of the results you’ll see this:

Note the Mind Map ‘button’ on the right-hand side. You click on that to generate a mind map based on the top 150 search results. In this example we used a search for prostate cancer:

Not only does this give a great topic overview it can support search as each branch and sub-branch is clickable to generate a new search.

Enjoy!